12-7219-41

antibody from Invitrogen Antibodies

Targeting: IL21 IL-21, Za11

Provider product page for 12-7219-41

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [20]
Comments [0]
Validations
Flow cytometry [1]
Other assay [6]

Submit

Product number: 12-7219-41 - Provider product page
Provider: Invitrogen Antibodies
Product name: IL-21 Monoclonal Antibody (eBio3A3-N2 (3A3-N2)), PE, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: The monoclonal antibody eBio3A3-N2 reacts with human IL-21, a potent stimulator of NK and cytolytic T cells. IL-21 is a 131 amino acid protein most closely related to IL-2 and IL-15. Expression is found in CD4+ cells upon activation. In addition to its effect on NK cells, IL-21 stimulates proliferation of B-cell stimulated by crosslinking of the CD40 antigen and stimulates the proliferation of bone marrow progenitor cells and the expression of the NK-cell marker CD56 in the presence of IL-15. Applications Reported: This eBio3A3-N2 (3A3-N2) antibody has been reported for use in intracellular staining followed by flow cytometric analysis. Applications Tested: This eBio3A3-N2 (3A3-N2) antibody has been pre-titrated and tested by intracellular staining of restimulated, Th17-polarized normal human peripheral blood cells. This can be used at 5 µL (0.5 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Staining for IL-21 has shown donor variability. stimulation times may vary depending on the donor and should be optimized. Increased staining levels have been observed on Th17-polarized normal human peripheral blood cells. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.
Reactivity: Human
Host: Mouse
Conjugate: Yellow dye
Isotype: IgG
Antibody clone number: eBio3A3-N2 (3A3-N2)
Vial size: 25 Tests
Concentration: 5 µL/Test
Storage: 4° C, store in dark, DO NOT FREEZE!

IL21 protein structure - 12-7219-41 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Mucosal gene expression and LP T cell producing IL-17A, IL-21, and IL-22 at baseline in inflamed and noninflamed mucosa. Gene expression was determined by rtPCR (a) and frequencies of IL-17A-, IL-21-, and IL-22-producing cells among LP CD3 + T cells were determined by flow cytometry (b). Gene expression data is displayed as the normalized ratios between the relative expression of the gene of interest and the housekeeping gene HPRT-1 . Wilcoxon signed-rank test for comparison was applied on paired samples (rtPCR: IL-17A n = 11; IL-21 n = 9; IL-22 n = 9; flow cytometry: n = 8 for each cytokine).
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Comparison of mucosal gene expression and LP T cells expressing IL-17A, IL-21, and IL-22 between baseline and week 4 of adalimumab treatment. Gene expression was determined by rtPCR (a) and frequencies of IL-17A-, IL-21-, and IL-22-producing cells among LP CD3 + T cells were determined by flow cytometry (b). Gene expression data is displayed as the normalized ratios between the relative expression of the gene of interest and the housekeeping gene HPRT-1 . Wilcoxon signed-rank test for comparison was applied on paired samples (rtPCR: IL-17A n = 12; IL-21 n = 11; IL-22 n = 11; flow cytometry: n = 7 for each cytokine).
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 2 Age promotes pre-Tfh cell differentiation in humans. Flow plots showing the frequency of CXCR5 + PD-1 + cells amongst CD4 + following 4 days in vitro activation of naive CD4 + T cells taken from younger (17-39 yrs) and older (>60 yrs) donors in the presence/absence IL-12 and TGFbeta (a). Percentage of CXCR5 + PD-1 + following activation of naive CD4 + T cells from younger and older donors in the absence (b) or presence (c) of IL-12 and TGFbeta. Percentage of CXCR5 + PD1 + cells following activation of naive CD4 + T cells from older donors with or without neutralising antibodies to IL-12, Activin A and TGFbeta (d). Bar graphs showing percentage of cells expressing pSTAT3 (e, f), and pSTAT5 (g, h) on day 3 of culture in presence/absence of IL-12 and TGFbeta in donors of the indicated ages. RT-PCR determination MAF (i), BCL6 (j), FOXP3 (k) and CXCL13 (l) following 4 days activation of naive CD4 + T cells from younger and older donors in the absence of polarising cytokines. Flow plots (m-o) and bar graphs (n-o) showing percentage of IFNgamma and IL-21 expressing cells following PMA and ionomycin mediated restimulation after 4 days in vitro culture of naive CD4 + T cells from younger and older donors in the absence of IL-12 and TGFbeta (m-o). Bar graph showing levels of IgG produced by B cells following co-culture with CD4+ T cells from day four cultures from young and older donors, in the presence/absence of Tfh-polarising cytokines (p). Each symbol is representative of
Conjugate: Yellow dye